Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Finding Study of BN80927 Administered as an Intravenous Infusion Once Every 3 Weeks in Patients With Advanced Malignant Solid Tumors

NCT01435096 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT01435096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01435096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Finding Study of BN80927 Administered as an Intravenous Infusion Once Every 3 Weeks in Patients With Advanced Malignant Solid Tumors
Lead sponsor
Ipsen
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2004
Completion date
October 31, 2007
Enrollment
56 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumour